| Identification | Back Directory | [Name]
Bimosiamose | [CAS]
187269-40-5 | [Synonyms]
TBC-1269
Bimosiamose
[1,1'-Biphenyl]-3-acetic acid, 3',3'''-(1,6-hexanediyl)bis[6'-(α-D-mannopyranosyloxy)- | [Molecular Formula]
C46H54O16 | [MOL File]
187269-40-5.mol | [Molecular Weight]
862.92 |
| Chemical Properties | Back Directory | [Melting point ]
115-117° | [Boiling point ]
1051.0±65.0 °C(Predicted) | [density ]
1.417±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:100.0(Max Conc. mg/mL);115.89(Max Conc. mM)
0.1 M NaOH:25.0(Max Conc. mg/mL);28.97(Max Conc. mM) | [form ]
A crystalline solid | [pka]
3.95±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
Bimosiamose (TBC-1269) is a nonoligosaccharide pan-selectin antagonist with IC50s of 88 μM, 20 μM, and 86 μM for E-selectin, P-selectin, and L-selectin, respectively. Bimosiamose has anti-inflammatory effects[1]. | [in vivo]
Bimosiamose (TBC-1269; 25 mg/kg; intravenous injection; Sprague-Dawley rats) treatment shows a significant increase in survival. Best overall survival, 70%, is observed when TBC-1269 is administered 15 minutes before reperfusion, and also shows a marked decrease in liver enzyme levels at 6 hours after reperfusion. Neutrophil migration is also significantly ameliorated (81%). The histologic damage scores is also improved[1]. | Animal Model: | Sprague-Dawley rats (200-225g) with ischemia and reperfusion (I/R)[1] | | Dosage: | 25 mg/kg | | Administration: | Intravenous injection | | Result: | Showed a significant increase in survival compared with controls. |
| [References]
[1] Palma-Vargas JM, et al. Small-molecule selectin inhibitor protects against liver inflammatory response after ischemia and reperfusion. J Am Coll Surg. 1997 Oct;185(4):365-72. PMID:9328385 |
|
|